

## AMBI Incorporated

[View the current AMBI Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/641-AMBI+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/641-AMBI+Incorporated.html>)

### Contact Details:

**4 Manhattenville Road**

Tel: 914 701 4500

**Purchase**

Fax: 914 696-0860

**NY**

Email: [mail@ambiinc.com](mailto:mail@ambiinc.com)

**10577-2197**

**United States of America**

AMBI Incorporated concentrates its business primarily on research, development, manufacturing, and sales of Nutrition Products. The Company supports the value of its Nutrition Products with "pharmaceutical-type" clinical trials. The Company's Nutrition Products are developed for consumers concerned primarily about cardiovascular health and diabetes.

### Recent Publications by AMBI Incorporated:



- [Ghrelin inhibits skeletal muscle protein breakdown in rats with thermal injury through normalizing elevated expression of E3 ubiquitin ligases MuRF1 and MAFbx.](#)  
*We previously determined that ghrelin synthesis was downregulated after...*6th June, 2009  
Department of Surgery, University of Cincinnati College of Medicine, 231- Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R893-901. Epub ([DOI Direct Link](#))
- [Neuropeptide Y \(NPY\) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: combined anorectic effects of Y2 and Y4 receptor-selective agonists.](#)  
*Peripheral administration of the endogenous Y(2) and Y(4) receptor...*14th April, 2007  
Department of Surgery, University of Cincinnati Medical Center, - Peptides. 2007 Feb;28(2):235-40. Epub 2007 Jan 3. ([DOI Direct Link](#))
- [Ghrelin stimulates food intake and growth hormone release in rats with thermal injury: synthesis of ghrelin.](#)  
*Ghrelin, a 28-residue octanoylated peptide recently isolated from the...*29th September, 2006  
Department of Surgery, University of Cincinnati College of Medicine, PO- Peptides. 2006 Jul;27(7):1624-31. Epub 2006 Mar 30. ([DOI Direct Link](#))
- [Nucleostemin is a marker of proliferating stromal stem cells in adult human bone marrow.](#)  
*The identification of stem cell-specific proteins and the elucidation of...*1st July, 2006

Academic Rheumatology, Department of Clinical Science at North Bristol,- Stem Cells. 2006 Apr;24(4):1113-20. Epub 2005 Nov 10. ([DOI Direct Link](#))

- [Neuropeptide Y \(NPY\) Y4 receptor selective agonists based on NPY\(32-36\): development of an anorectic Y4 receptor selective agonist with picomolar affinity.](#)  
*We have previously shown [Cys-Trp-Arg-Nva-Arg-Tyr-NH(2)](2), 1, to be a...*23rd May, 2006  
Division of Gastrointestinal Hormones, Department of Surgery and- J Med Chem. 2006 Apr 20;49(8):2661-5. ([DOI Direct Link](#))
- [Production logistics of 177Lu for radionuclide therapy.](#)  
*Owing to its favourable decay characteristics 177Lu [T(1/2)=6.71 d,...*3rd December, 2003  
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai 400- Appl Radiat Isot. 2003 Aug-Sep;59(2-3):109-18.
- [188Re-labeled hydroxyapatite particles for radiation synovectomy.](#)  
*A new procedure for labeling hydroxyapatite (HA) particles with 188Re for...*9th August, 2003  
Radiopharmaceuticals Section, Isotope Division, Bhabha Atomic Research- Appl Radiat Isot. 2003 Apr;58(4):463-8.
- [Neuropeptide Y \(NPY\) family of hormones: progress in the development of receptor selective agonists and antagonists.](#)  
*Neuropeptide Y (NPY), the most abundant peptide present in the mammalian...*12th July, 2003  
Division of Gastrointestinal Hormones, Department of Surgery, University- Curr Pharm Des. 2003;9(15):1165-75.
- [Bis\(31/31'\)\[\[Cys\(31\). Nva\(34\)\]NPY\(27-36\)-NH\(2\)\]: a neuropeptide Y \(NPY\) Y\(5\) receptor selective agonist with a latent stimulatory effect on food intake in rats.](#)  
*The actions of neuropeptide Y (NPY) are mediated by at least six G-protein...*26th March, 2003  
Department of Surgery, University of Cincinnati and VA Medical Center, 231- Peptides. 2002 Aug;23(8):1485-90.
- [Parathyroid hormone may be a cancer promoter - an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D.](#)  
*Epidemiological studies reporting an inverse association between sunlight...*10th June, 2000  
Nutrition 21/AMBI, San Diego, CA, USA.- Med Hypotheses. 2000 Mar;54(3):475-82. ([DOI Direct Link](#))
- [Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity.](#)  
*Amino acids modulate the secretion of both insulin and glucagon; the...*25th March, 2000  
Nutrition 21/AMBI, San Diego, CA, USA.- Med Hypotheses. 1999 Dec;53(6):459-85. ([DOI Direct Link](#))

#### Press Releases on AMBI Incorporated:

<a href="#">Reportlinker Adds Blood Banking and Blood Products - Global Market Perspective</a>	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Blood Banking and Blood Products - Global Market Perspective <a href="http://www">http://www</a>
--	---------------------	--------------	--

<a href="#">Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference</a>	24th November, 2009	Quest Diagnostics	MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is
<a href="#">Prodesse's ProParaflu+(TM) Assay Cleared for US Marketing by FDA</a>	24th November, 2009	Gen-Probe Incorporated	Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated
<a href="#">Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio</a>	24th November, 2009	Aflac Incorporated	COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by
<a href="#">WellTek Positioned to Capitalize on Trends in Health and Fitness</a>	24th November, 2009	WellTek Incorporated	ORLANDO, Fla., Nov. 24 /PRNewswire-FirstCall/ -- Two thirds of adults are overweight and one third of those are obese. Experts estimate that 80 percent of the population will experience a back

#### AMBI Incorporated Patents:



- 7328697- [Radiant tube heater assembly](#)
- 5914326- [Method for promoting weight and fat loss](#)
- 5910479- [Method for the treatment of Streptococcus pneumoniae infection](#)
- 5905075- [Chromium nicotinate compositions and uses thereof](#)
- 5866539- [Method for the control of antibiotic-resistant gram positive bacteria and treatment of infection](#)
- 5858962- [Composition for treating mastitis and other staphylococcal infections](#)
- 5833958- [Dentifrice compositions](#)
- 5804549- [Compositions with activity against helicobacter](#)
- 5763395- [Stabilized lanthionine bacteriocin compositions](#)
- 5762948- [Moist bacteriocin disinfectant wipes and methods of using the same](#)
- 5760026- [Method for treating mastitis and other staphylococcal infections](#)
- 5753614- [Nisin compositions for use as enhanced, broad range bactericides](#)
- 5691301- [Nisin compositions for use as enhanced, broad range bactericides](#)

- 5626125- [Space heating appliances](#)
- 5479912- [Space heating appliances](#)
- 4892084- [Space heating appliance](#)
- 5948772- [Chromium picolinate compositions and uses thereof](#)
- 5980905- [Chromium polynicotinate compositions and uses thereof](#)
- 5985823- [Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon](#)
- 6713469- [Chromium picolinate compositions and uses thereof](#)
- 6569830- [Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains](#)
- 6471998- [Chromium picolinate compositions](#)
- 6432942- [Chromium picolinate compositions and uses thereof](#)
- 6323192- [Chromium polynicotinate compositions and uses thereof for absorption of essential metals](#)
- 6251889- [Chromium picolinate compositions](#)
- 6251888- [Chromium picolinate compositions and uses thereof](#)
- 6217320- [Space heating appliances](#)
- 6156332- [Method and composition for masking mineral taste](#)
- 6143301- [Chromium picolinate compositions and uses thereof](#)
- 6136317- [Chromium picolinate compositions](#)
- 6100251- [Chromium polynicotinate compositions](#)
- 6100250- [Enteric-coated chromium polynicotinate compositions and uses thereof](#)
- 6093711- [Enteric-coated chromium picolinate compositions and uses thereof](#)
- 6028051- [Method for the treatment of staphylococcal disease](#)
- 4869230- [Space heating appliance](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

